Registry rank 970 · Portfolio as of 2026-03-31

EQUITY INDEX FUND

GEQYX · GEQZX

Best-fit active share6.0%vs IVV · fund as of 2026-03-31 · proxy as of 2026-03-31

Declared-benchmark active share6.0%S&P 500® Index · benchmark match · fund as of 2026-03-31 · proxy as of 2026-03-31 · declared source as of 2025-12-31

GEQYX expense ratio0.12%SEC expense filing · as of 2025-12-31

GEQYX fee per active unit1.99%expense as of 2025-12-31; fund as of 2026-03-31; proxy as of 2026-03-31

Filed fees in dollars

SEC-convention illustration

Computed from SEC filings

Assumptions for each dollar figure: $100,000 starting amount · 5.0% annual return · annual compounding · fees deducted annually · 0.01% computed index-control baseline. Methodology.

Illustrated difference between each class’s filed expense ratio and the computed index-control baseline. Computed from SEC filings.
Share class and filing	10 years	20 years	30 years
GEQYX0.12% · SEC expense filing · as of 2025-12-31	$1,697	$5,494	$13,342
GEQZX0.39% · SEC expense filing · as of 2025-12-31	$5,795	$18,525	$44,420

Real trailing windows

Computed on licensed market-return history

Trailing windows use IVV adjusted-close total-return history through 2026-07-29 and the same filed index-control fee baseline as the convention table. Methodology.

Dollar fee drag over actual trailing proxy-return windows. Each result below is computed on licensed market-return history.
Share class and filing	10 years	20 years	30 years
GEQYXFiled fee as of 2025-12-31	$3,812Computed on licensed market-return history 2016-07-29 to 2026-07-29 · proxy return 14.88% annualized	$16,319Computed on licensed market-return history 2006-07-31 to 2026-07-29 · proxy return 11.19% annualized	Proxy history begins 2000 — no full 30-year window
GEQZXFiled fee as of 2025-12-31	$13,031Computed on licensed market-return history 2016-07-29 to 2026-07-29 · proxy return 14.88% annualized	$55,098Computed on licensed market-return history 2006-07-31 to 2026-07-29 · proxy return 11.19% annualized	Proxy history begins 2000 — no full 30-year window

Index-control tracking difference

Annualized fund NAV return minus the matched proxy return. Positive means the fund NAV return was higher over that window.

Derived annualized percentages only. Each result below is computed on licensed market-return history.
Fund NAV class	10 years	20 years	30 years
GEQYX	-0.18%Computed on licensed market-return history 2016-07-29 to 2026-07-29	-0.62%Computed on licensed market-return history 2006-07-31 to 2026-07-29	no exact shared fund NAV/proxy anchors for a full 30-year window
GEQZX	-0.39%Computed on licensed market-return history 2016-07-29 to 2026-07-29	-0.53%Computed on licensed market-return history 2006-07-31 to 2026-07-29	no exact shared fund NAV/proxy anchors for a full 30-year window

These figures are illustrations, not predictions or personalized advice. Returns and fees can differ. Read the research disclaimer.

Change the illustration

Return mode 5% SEC convention Real trailing window

Share classStarting amount ($)YearsAnnual return (%)

Computed from SEC filings

Assumptions for the dollar figures below: $100,000 starting amount; 5.0% annual return; 20 years; annual compounding; fees deducted annually; 0.01% computed index-control baseline. GEQYX SEC expense filing, as of 2025-12-31. Methodology.

SEC-convention illustration for GEQYX; expense ratio filed as of 2025-12-31.
Result	Amount
Ending value at baseline	$264,825
Ending value at filed expense ratio	$259,330
Difference attributed to fee drag	$5,494

This is an illustration, not a prediction or personalized advice. Returns and fees can differ. Read the research disclaimer.

Largest active differences vs IVV

The bars are labeled and repeated in the table; color is not the only signal. Linked company names open Buy Like Buffett’s company record; Sensible Investor does not score stocks.

Johnson & Johnson-1.05%

AbbVie, Inc.-0.69%

Merck & Co., Inc.-0.53%

Philip Morris International, Inc.-0.46%

UnitedHealth Group, Inc.-0.44%

Abbott Laboratories-0.32%

Bristol-Myers Squibb Co.+0.31%

Pfizer, Inc.-0.29%

Zoetis, Inc.+0.21%

Altria Group, Inc.-0.20%

Holding	Fund	IVV	Difference
Johnson & Johnson	0.00%	1.05%	-1.05%
AbbVie, Inc.	0.00%	0.69%	-0.69%
Merck & Co., Inc.	0.00%	0.53%	-0.53%
Philip Morris International, Inc.	0.00%	0.46%	-0.46%
UnitedHealth Group, Inc.	0.00%	0.44%	-0.44%
Abbott Laboratories	0.00%	0.32%	-0.32%
Bristol-Myers Squibb Co.	0.53%	0.22%	+0.31%
Pfizer, Inc.	0.00%	0.29%	-0.29%
Zoetis, Inc.	0.30%	0.09%	+0.21%
Altria Group, Inc.	0.00%	0.20%	-0.20%

Source and verification

SEC N-PORT filing · filed 2026-05-28 · period 2026-03-31

SEC expense filing · period 2025-12-31

Immutable verification record · Active-share method

Cite these figures

Each snippet includes the figure’s source-event date and immutable verification URL.

Best-fit active share

Sensible Investor, “EQUITY INDEX FUND — best-fit active share,” 6.0% versus IVV, fund portfolio as of 2026-03-31. https://sensible-investor.com/registry/geqyx/as-of/363649da-fcfb-4007-87ef-de06de7710ca

GEQYX filed expense ratio

Sensible Investor, “EQUITY INDEX FUND — filed expense ratio,” 0.12% for GEQYX, as of 2025-12-31. https://sensible-investor.com/registry/geqyx/as-of/363649da-fcfb-4007-87ef-de06de7710ca

GEQYX fee per active unit

Sensible Investor, “EQUITY INDEX FUND — fee per unit of active management,” 1.99% using the GEQYX expense ratio as of 2025-12-31 and fund portfolio as of 2026-03-31. https://sensible-investor.com/registry/geqyx/as-of/363649da-fcfb-4007-87ef-de06de7710ca